NCT03900572 is a Phase 1 clinical trial of HPV Vaccine in HPV Infections, sponsored by Shanghai Zerun Biotechnology Co.,Ltd.

Who is sponsoring NCT03900572?

NCT03900572 is sponsored by Shanghai Zerun Biotechnology Co.,Ltd.

What drugs are being tested in NCT03900572?

Interventions in NCT03900572: HPV Vaccine, Placebo.

What condition does NCT03900572 study?

NCT03900572 studies HPV Infections.

Is NCT03900572 still recruiting?

NCT03900572 is currently completed. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT03900572

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Completed Phase 1 Last updated 13 April 2023

What this trial tests

Phase 1 trial testing HPV Vaccine in HPV Infections in 90 participants. Completed in 30 April 2020.

Timeline

9 March 2019

Primary endpoint
30 April 2020

30 April 2020

Quick facts

Lead sponsor	Shanghai Zerun Biotechnology Co.,Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	90
Start date	9 March 2019
Primary completion	30 April 2020
Estimated completion	30 April 2020
Sites	1 location across China

Drugs / interventions tested

HPV Vaccine — full drug profile →
Placebo

Conditions studied

HPV Infections — all drugs for HPV Infections →

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd — full company profile →

Who can join

Adults 9 to 45, female only, with HPV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of HPV Vaccine

Trials testing the same drug.

NCT05202860 — Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis · Phase 2 · active not recruiting
NCT01735006 — Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine · Phase 3 · completed

Other recruiting trials for HPV Infections

Currently open trials in the same condition.

NCT05027776 — Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years · Phase 3 · recruiting

Other Shanghai Zerun Biotechnology Co.,Ltd trials

Trials by the same sponsor.

NCT04965350 — Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females · Phase 3 · completed
NCT02733068 — A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03900572 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zerun Biotechnology Co.,Ltd
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing